

## Neuronetics, Inc. Supplemental Financial and Operating Information

For the period ended December 31, 2020

Revenue (\$ thousands)	2019				2020	2020	2020	2020	2019	2020
	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	FY	FY
<b>NeuroStar Capital (1)</b>	<b>\$2,939</b>	<b>\$4,034</b>	<b>\$4,264</b>	<b>\$4,959</b>	<b>\$2,410</b>	<b>\$2,224</b>	<b>\$2,438</b>	<b>\$3,446</b>	<b>\$16,196</b>	<b>\$10,518</b>
YoY Change	54%	23%	24%	14%	-18%	-45%	-43%	-31%	25%	-35%
NeuroStar Operating Lease (2)	\$182	\$187	\$184	\$177	\$155	\$114	\$88	\$79	\$730	\$437
YoY Change	-29%	3%	-31%	-24%	-15%	-39%	-52%	-55%	-22%	-40%
Other (3)	\$229	\$407	\$167	\$278	\$29	\$0	\$15	\$96	\$1,081	\$140
YoY Change	11%	239%	-21%	50%	-87%	-100%	-91%	-66%	50%	-87%
<b>Total U.S. NeuroStar Advanced Therapy System Revenues</b>	<b>\$3,350</b>	<b>\$4,628</b>	<b>\$4,616</b>	<b>\$5,413</b>	<b>\$2,594</b>	<b>\$2,338</b>	<b>\$2,541</b>	<b>\$3,620</b>	<b>\$18,007</b>	<b>\$11,094</b>
YoY Change	41%	30%	18%	14%	-23%	-49%	-45%	-33%	23%	-38%
<b>Total U.S. Treatment Sessions Revenues</b>	<b>\$8,778</b>	<b>\$10,847</b>	<b>\$10,252</b>	<b>\$11,243</b>	<b>\$8,193</b>	<b>\$6,547</b>	<b>\$9,083</b>	<b>\$11,029</b>	<b>\$41,120</b>	<b>\$34,852</b>
YoY Change	21%	22%	11%	13%	-7%	-40%	-11%	-2%	17%	-15%
<b>Total U.S. Other Revenues</b>	<b>\$418</b>	<b>\$415</b>	<b>\$426</b>	<b>\$374</b>	<b>\$390</b>	<b>\$382</b>	<b>\$404</b>	<b>\$397</b>	<b>\$1,633</b>	<b>\$1,574</b>
YoY Change	16%	1%	9%	-12%	-7%	-8%	-5%	6%	3%	-4%
<b>Total U.S. Revenues</b>	<b>\$12,546</b>	<b>\$15,890</b>	<b>\$15,294</b>	<b>\$17,030</b>	<b>\$11,177</b>	<b>\$9,267</b>	<b>\$12,029</b>	<b>\$15,046</b>	<b>\$60,760</b>	<b>\$47,519</b>
YoY Change	26%	23%	13%	13%	-11%	-42%	-21%	-12%	18%	-22%
<b>Total International Revenues</b>	<b>\$182</b>	<b>\$682</b>	<b>\$706</b>	<b>\$326</b>	<b>\$299</b>	<b>\$474</b>	<b>\$419</b>	<b>\$533</b>	<b>\$1,896</b>	<b>\$1,725</b>
YoY Change	1%	93%	222%	-40%	64%	-31%	-41%	64%	46%	-9%
<b>Total Revenues</b>	<b>\$12,728</b>	<b>\$16,572</b>	<b>\$16,000</b>	<b>\$17,356</b>	<b>\$11,476</b>	<b>\$9,741</b>	<b>\$12,448</b>	<b>\$15,579</b>	<b>\$62,656</b>	<b>\$49,244</b>
YoY Change	25%	25%	16%	11%	-10%	-41%	-22%	-10%	19%	-21%
U.S. Operating and Financial Metrics	2019				2020	2020	2020	2020	2019	2020
	Q1	Q2	Q3	Q4	Q1	Q1	Q1	Q1	FY	FY
<b>Active Installed Base</b>										
Active Installed Base - End of Period	931	976	1,032	1,085	1,119	1,122	1,143	1,170	1,085	1,170
<b>Total NeuroStar Systems Sold (4)</b>	<b>43</b>	<b>61</b>	<b>68</b>	<b>78</b>	<b>38</b>	<b>35</b>	<b>39</b>	<b>54</b>	<b>250</b>	<b>166</b>
YoY Change	79%	42%	45%	28%	-12%	-43%	-43%	-31%	43%	-34%
<b>Active Sites</b>										
Active Sites - End of Period	737	778	833	870	884	889	909	916	870	916
<b>Average Revenue Per Active Site (\$) (5)</b>	<b>\$12,415</b>	<b>\$14,718</b>	<b>\$13,177</b>	<b>\$13,497</b>	<b>\$9,418</b>	<b>\$7,406</b>	<b>\$10,218</b>	<b>\$12,133</b>	<b>\$58,162</b>	<b>\$40,060</b>
YoY Change	NA	1%	-9%	-8%	-24%	-50%	-22%	-10%	12%	-31%

(1) = Revenue from Capital Sales and Sales Type Leases

(2) = Revenue derived from Operating Lease revenue during the period

(3) = Primarily includes revenue derived from Treatment Coils in US

(4) = Includes all U.S. systems sold during the period, both as Capital Sales or Sales-Type-Leases

(5) = Total U.S. Treatment Session Revenue / Active Sites (End of Prior Period)